The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT

A J Vangsted; T W Klausen; W Ruminski; P Gimsing; N F Andersen; A O Gang; N Abildgaard; L M Knudsen; J L Nielsen; H Gregersen; U Vogel

doi:10.1038/bmt.2008.351

The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT

A J Vangsted, T W Klausen, W Ruminski, P Gimsing, N F Andersen, A O Gang, N Abildgaard, L M Knudsen, J L Nielsen, H Gregersen, U Vogel

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

28 Citationer (Scopus)

Abstract

Udgivelsesdato: 2009

Originalsprog	Engelsk
Tidsskrift	Bone Marrow Transplantation
Vol/bind	43
Udgave nummer	7
Sider (fra-til)	539-45
Antal sider	6
ISSN	0268-3369
DOI	https://doi.org/10.1038/bmt.2008.351
Status	Udgivet - 2008

Bibliografisk note

Keywords: Aged; Female; Haplotypes; Humans; Interleukin-1beta; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Polymorphism, Single Nucleotide; Prognosis; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous

Adgang til dokumentet

10.1038/bmt.2008.351

Citationsformater

Vangsted, A. J., Klausen, T. W., Ruminski, W., Gimsing, P., Andersen, N. F., Gang, A. O., Abildgaard, N., Knudsen, L. M., Nielsen, J. L., Gregersen, H., & Vogel, U. (2008). The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplantation, 43(7), 539-45. https://doi.org/10.1038/bmt.2008.351

The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. / Vangsted, A J; Klausen, T W; Ruminski, W; Gimsing, P; Andersen, N F; Gang, A O; Abildgaard, N; Knudsen, L M; Nielsen, J L; Gregersen, H; Vogel, U.

I: Bone Marrow Transplantation, Bind 43, Nr. 7, 2008, s. 539-45.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Vangsted, AJ, Klausen, TW, Ruminski, W, Gimsing, P, Andersen, NF, Gang, AO, Abildgaard, N, Knudsen, LM, Nielsen, JL, Gregersen, H & Vogel, U 2008, 'The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT', Bone Marrow Transplantation, bind 43, nr. 7, s. 539-45. https://doi.org/10.1038/bmt.2008.351

@article{dd813ee0746811df928f000ea68e967b,

title = "The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT",

abstract = "Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations leading to a modified expression of these cytokines will influence the outcome for these patients. We investigated 348 MM patients undergoing high-dose melphalan treatment followed by Auto-SCT and examined the influence of single nucleotide polymorphisms (SNPs) in genes involved in the inflammatory response. We found that the polymorphism IL-1beta T-31C significantly influenced overall survival (OS; P=0.02) and that carriers of the variant C-allele had a significantly longer survival than homozygous wild-type allele TT-carriers (relative risk 0.6 (95% CI=0.5-0.9); P=0.008). The polymorphisms IL-6 G-174C, IL-10 C592A, PPARgamma2 Pro(12)Ala, COX-2 A-1195G, COX-2 T8473C and NFKB1 ins/del did not influence the OS in this group of patients. Furthermore, homozygous carriers of the variant allele of IL-1beta T-31C were at 1.37-fold (CI=1.05-1.80) increased risk of MM as compared with population-based controls (P=0.02). Our results indicate that IL-1beta is involved in the pathogenesis of MM.",

author = "Vangsted, {A J} and Klausen, {T W} and W Ruminski and P Gimsing and Andersen, {N F} and Gang, {A O} and N Abildgaard and Knudsen, {L M} and Nielsen, {J L} and H Gregersen and U Vogel",

note = "Keywords: Aged; Female; Haplotypes; Humans; Interleukin-1beta; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Polymorphism, Single Nucleotide; Prognosis; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous",

year = "2008",

doi = "10.1038/bmt.2008.351",

language = "English",

volume = "43",

pages = "539--45",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "nature publishing group",

number = "7",

}

TY - JOUR

T1 - The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT

AU - Vangsted, A J

AU - Klausen, T W

AU - Ruminski, W

AU - Gimsing, P

AU - Andersen, N F

AU - Gang, A O

AU - Abildgaard, N

AU - Knudsen, L M

AU - Nielsen, J L

AU - Gregersen, H

AU - Vogel, U

N1 - Keywords: Aged; Female; Haplotypes; Humans; Interleukin-1beta; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Polymorphism, Single Nucleotide; Prognosis; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous

PY - 2008

Y1 - 2008

N2 - Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations leading to a modified expression of these cytokines will influence the outcome for these patients. We investigated 348 MM patients undergoing high-dose melphalan treatment followed by Auto-SCT and examined the influence of single nucleotide polymorphisms (SNPs) in genes involved in the inflammatory response. We found that the polymorphism IL-1beta T-31C significantly influenced overall survival (OS; P=0.02) and that carriers of the variant C-allele had a significantly longer survival than homozygous wild-type allele TT-carriers (relative risk 0.6 (95% CI=0.5-0.9); P=0.008). The polymorphisms IL-6 G-174C, IL-10 C592A, PPARgamma2 Pro(12)Ala, COX-2 A-1195G, COX-2 T8473C and NFKB1 ins/del did not influence the OS in this group of patients. Furthermore, homozygous carriers of the variant allele of IL-1beta T-31C were at 1.37-fold (CI=1.05-1.80) increased risk of MM as compared with population-based controls (P=0.02). Our results indicate that IL-1beta is involved in the pathogenesis of MM.

AB - Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations leading to a modified expression of these cytokines will influence the outcome for these patients. We investigated 348 MM patients undergoing high-dose melphalan treatment followed by Auto-SCT and examined the influence of single nucleotide polymorphisms (SNPs) in genes involved in the inflammatory response. We found that the polymorphism IL-1beta T-31C significantly influenced overall survival (OS; P=0.02) and that carriers of the variant C-allele had a significantly longer survival than homozygous wild-type allele TT-carriers (relative risk 0.6 (95% CI=0.5-0.9); P=0.008). The polymorphisms IL-6 G-174C, IL-10 C592A, PPARgamma2 Pro(12)Ala, COX-2 A-1195G, COX-2 T8473C and NFKB1 ins/del did not influence the OS in this group of patients. Furthermore, homozygous carriers of the variant allele of IL-1beta T-31C were at 1.37-fold (CI=1.05-1.80) increased risk of MM as compared with population-based controls (P=0.02). Our results indicate that IL-1beta is involved in the pathogenesis of MM.

U2 - 10.1038/bmt.2008.351

DO - 10.1038/bmt.2008.351

M3 - Journal article

C2 - 18997828

VL - 43

SP - 539

EP - 545

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -